| Objective:To investigate the effects of autologous platelet-rich plasma (PRP) intrauterine perfusion combine with leuprorelin on endometrial receptivity, ovarian function and pregnancy outcomes in patients with endometriosis (EMs) and infertility.Method:90 patients with EMs and infertility who were admitted to our hospital from April 2022 to December 2023 were selected, they were divided into control group (45 cases) and experimental group (45 cases) according to random number table method, both groups received laparoscopic surgery, the control group received leuprorelin treatment after surgery, and the experimental group received PRP intrauterine perfusion on the basis of the control group. The Efficacy, endometrial receptivity indexes, ovarian function indexes [luteinizing hormone (LH), anti-Muller hormone (AMH), follicle-stimulating hormone (FSH), estradiol (E2)], pregnancy rate at 6 and 12 months after surgery, tubal patency rate at 12 months after surgery, and recurrence rate of EMs and incidence of adverse reactions were compared between the two groups.Results:Compared with the control group after treatment, the total clinical effective rate, AMH, pregnancy rate at 12 months after surgery, tubal patency rate at 12 months after surgery in the experimental group were higher, the endometrial thickness was increased, and the uterine artery resistance index, uterine artery pulse index, E2, FSH, LH and the recurrence rate of EMs at 12 months after surgery were lower (P<0.05). There was no difference in the pregnancy rate at 6 months after surgery and the incidence of adverse reactions between the two groups (P>0.05). Conclusion:PRP intrauterine perfusion combine with leuprorelin can effectively improve endometrial receptivity, ovarian function and pregnancy outcome in patients with EMs and infertility, which is safe and reliable. |
